With Sanofi still on board, Click Therapeutics closes $52M series B for digital therapeutics in depression, chronic pain and more (Fierce Biotech):
Another medtech developer’s plans to create digital therapeutics to treat a wide range of illnesses are clicking into place, thanks to a third multimillion-dollar investment in Click Therapeutics in barely a year.
Click has already validated and begun the commercial launch of its first product, Clickotine, a mobile software program for smoking cessation … Several more of Click’s app-based therapeutics—all of which will require a physician’s prescription and therefore FDA clearance—are undergoing clinical trials and run the gamut of medical targets. The furthest along of these is a program to treat major depressive disorder, developed in partnership with Otsuka. A phase 3 trial of the program hosted on Verily’s Baseline platform is now studying the abilities of several cognitive exercises to lessen the symptoms of depression.
Close behind in phase 2 trials are Click’s work to treat migraine and schizophrenia—the latter of which is a collaboration with Boehringer Ingelheim—as well as the cleverly named Clickadian, for insomnia, and Clickheart, for acute coronary syndrome. Digital therapeutics for overactive bladder, chronic lower back pain and obesity, meanwhile, are still in the earliest stages of clinical study.
Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth Partners and Accelmed Partners (press release):
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing. The financing round was co-led by new investors H.I.G. BioHealth Partners (“H.I.G. BioHealth”) and Accelmed Partners II (“Accelmed”), with participation from Health Catalyst Capital, Revelation Partners, and a top biotechnology hedge fund, and from existing investors Sanofi Ventures, K2 HealthVentures, Hikma Ventures, and Ridgetop Health. Proceeds from the Series B financing will be used to accelerate the development and commercialization of Click’s internal prescription digital therapeutic pipeline and advance Click’s platform capabilities.
Click’s pipeline of innovative digital therapeutics spans multiple therapeutic areas, from psychiatry and chronic pain to cardiometabolic and autoimmune disorders. In addition to its internal pipeline programs, Click has entered into landmark collaboration agreements with Otsuka to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder (MDD), and with Boehringer Ingelheim to develop and commercialize a prescription-based digital therapeutic to aid in the treatment of schizophrenia.